Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.68% | -28.78% | -23.33% | 13.14% | 22.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.68% | -28.78% | -23.33% | 13.14% | 22.82% |
| Cost of Revenue | -29.41% | -24.49% | -6.61% | 7.19% | 59.92% |
| Gross Profit | -23.55% | -31.17% | -32.41% | 16.78% | 8.48% |
| SG&A Expenses | -35.86% | -23.29% | 10.80% | 6.01% | 21.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.88% | -23.84% | 3.08% | 6.86% | 35.60% |
| Operating Income | 10.48% | -50.24% | -117.78% | 64.18% | -16.63% |
| Income Before Tax | -17.34% | -43.25% | -121.19% | 117.16% | -5.83% |
| Income Tax Expenses | -265,112.50% | -375.00% | -- | 350.00% | -260.00% |
| Earnings from Continuing Operations | 1,119.95% | -42.49% | -121.23% | 116.01% | -5.19% |
| Earnings from Discontinued Operations | -693.75% | -21.95% | -44.59% | -2.88% | -78.67% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,104.52% | -45.64% | -126.26% | 132.63% | -7.88% |
| EBIT | 10.48% | -50.24% | -117.78% | 64.18% | -16.63% |
| EBITDA | 11.09% | -47.38% | -113.60% | 65.01% | -15.25% |
| EPS Basic | 1,491.17% | -46.03% | -125.98% | 130.00% | -31.80% |
| Normalized Basic EPS | 19.79% | -43.68% | -120.96% | 114.74% | -7.78% |
| EPS Diluted | 153.90% | -90.46% | -126.16% | -65.37% | -31.58% |
| Normalized Diluted EPS | 116.31% | -90.92% | -121.08% | -65.61% | -91.82% |
| Average Basic Shares Outstanding | 0.48% | 0.73% | 1.07% | 1.14% | 1.75% |
| Average Diluted Shares Outstanding | -44.28% | 526.16% | 0.50% | 531.93% | 1,045.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |